Piperazine derivatives as stearoyl-coa desaturase inhibitors...

Details Piperazine derivatives as stearoyl-coa desaturase inhibitors... Piperazine derivatives as stearoyl-coa desaturase inhibitors...

2008-10-08

2011-10-04

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S359000

Reexamination Certificate

active

08030488

ABSTRACT:
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I):where G, J, L, M, x, y, W, V, R2, R3, R4, R5, R6, R7, R8, R8a, R9, R9a, R10, R10a, R11and R11aare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

REFERENCES:
patent: 4423049 (1983-12-01), Temple, Jr.
patent: 4843078 (1989-06-01), Ishizumi et al.
patent: 5444059 (1995-08-01), Frigola-Constansa et al.
patent: 5681956 (1997-10-01), Thurkauf et al.
patent: 6288230 (2001-09-01), Chen et al.
patent: 7335658 (2008-02-01), Chakka et al.
patent: 983493 (1976-02-01), None
patent: 2476065 (2003-09-01), None
patent: 23 41 925 (1975-03-01), None
patent: 0188094 (1986-07-01), None
patent: 1334972 (2003-08-01), None
patent: 1452525 (2004-09-01), None
patent: 61-043173 (1986-03-01), None
patent: 61087672 (1986-05-01), None
patent: 96/16040 (1996-05-01), None
patent: 01/62954 (2001-08-01), None
patent: 01/96327 (2001-12-01), None
patent: 02/10154 (2002-02-01), None
patent: 03/050088 (2003-06-01), None
patent: 03/075929 (2003-09-01), None
patent: 03/076422 (2003-09-01), None
patent: 03/091247 (2003-11-01), None
patent: 03/092686 (2003-11-01), None
patent: 2004/080976 (2004-09-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Office Action issued Mar. 6, 2009, by the Canadian Intellectual Property Office in related-Canadian Patent Application No. 2,533,901 (7 pages).
Examiner's Report issued Nov. 17, 2009, by the Canadian Intellectual Property Office in related Canadian Patent Application No. 2,533,901 (2 pages) (Note: The references cited in this Examiner's Report have been previously submitted in the IDS filed with the USPTO on Jan. 23, 2009.).
EPO Communication pursuant to Article 94(3) EPC (Office Action) issued Aug. 23, 2010, by the European Patent Office, in related European Patent Application No. EP-04779656.0 (4 pages).
Official Action issued Oct. 26, 2010, by the Japan Patent Office in related Japanese Patent Application No. JP-2006-522096, with English translation (7 pages).
Gotor, V., et al., “Fungal and Bacterial Regioselective Hydroxylation of Pyrimidine Heterocycles”; Tetrahedron, Elsevier Science Publishers, Amsterdam, NL; vol. 53, No. 18 (May 5, 1997); pp. 6421-6432. (Previously submitted in the parent U.S. Appl. No. 10/567,009, filed Jan. 30, 2006, and previously referenced in our IDS filed Jan. 23, 2009.).
Gotor V. et al. “Fungal and Bacterial Regioselective Hydroxylation of Pyrimidine Heterocycles”, Tetrahedron, Elsevier Science Publishers, Amsterdam, NL, vol. 53, No. 18, (May 5, 1997), pp. 6421-6432 (previously submitted in U.S. Appl. No. 10/567,009, filed Jan. 30, 2006 (parent application).
International Search Report for PCT/US2004/024658, published Feb. 2, 2005 (4 pages) (previously submitted in U.S. Appl. No. 10/567,009, filed Jan. 30, 2006 (parent application).
Official Action issued Jul. 14, 2008, by the Canadian Intellectual Property Office in related Canadian Application No. 2,533,901 (3 pages).
Substantive Examination Adverse Report and Search Report dated Dec. 18, 2008, from the Malaysian Patent Office in related-Malaysian Application No. PI-20060382 (3 pages).
Regnier, G. L., et al., “Triphenylpropylpiperazine derivatives as new potent analgetic substances”; Journal of Medicinal Chemistry, Mar. 1972; LNKD-PUBMED: 5059214, vol. 15, No. 3 (Mar. 1972); XP002628470, ISSN: 0022-2623; pp. 295-301.
Awaya, Akira, et al., “Neurotropic Pyrimidine Heterocyclic Compounds. I. The Newly Synthesized Pyrimidine Compounds Promote Neurite Outgrowth of GOTO and Neuro 2a Neuroblastoma Cell Lines, and Potentiate Nerve Growth Factor (NGF)-Induced Neurite Sprouting of PC 12 Cells”; Biological and Pharmaceutical Bulletin, vol. 16, No. 3 (1993); XP002628471, ISSN: 0918-6158; pp. 248-253.
Ishizumi, K., et al., “Synthesis and Anxiolytic Activity of N-Substituted Cyclic Imides (1R*, 2S*, 3R*,4S*)-N-4-4-(2-Pyrimidiny1)-1-piperazinyl]butyl]-2,3-bicyclo[2.2.1]heptanedicarboximide (Tandospirone) and Related Compounds”; Chemical and Pharmaceutical Bulletin (Tokyo), vol. 39, No. 9 (1991); XP002628472, ISSN: 0009-2363; pp. 2288-2300.
Extended European Search Report and Written Opinion dated Mar. 29, 2011, issued by the European Patent Office in related European Patent Application No. 10184745.7 (14 pages).
Official Action issued Jun. 9, 2011, by the State Intellectual Property Office of the People's Republic of China in related Chinese Patent Application No. 200910207686.0, 8 pages.

Affiliated with

Also associated with

Rating

Piperazine derivatives as stearoyl-coa desaturase inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperazine derivatives as stearoyl-coa desaturase inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives as stearoyl-coa desaturase inhibitors... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4295629